{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:09:17Z","timestamp":1792789757599,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["000000005811"],"award-info":[{"award-number":["000000005811"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BHSF Foundation","award":["000000006064"],"award-info":[{"award-number":["000000006064"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15224-3","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:55:17Z","timestamp":1764809717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2 positive breast cancer (TUTOR): Study protocol for a multicenter phase 1 clinical trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Zouina","family":"Sarfraz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Ozair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mainak","family":"Bardhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Starosciak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilanis C.","family":"Perche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia C.","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazmin","family":"Odia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minesh P.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Maharaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cristina Sandoval","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Mahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmeet S.","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"15224_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15\u201323.","journal-title":"Breast"},{"key":"15224_CR2","unstructured":"Institute NC. Cancer Stat Facts: Female Breast Cancer Subtypes 2024 [Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html."},{"issue":"1","key":"15224_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08708-5","volume":"21","author":"MD Hackshaw","year":"2021","unstructured":"Hackshaw MD, Danysh HE, Henderson M, Wang E, Tu N, Islam Z, et al. Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review. BMC Cancer. 2021;21(1):967.","journal-title":"BMC Cancer"},{"key":"15224_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","volume":"40","author":"M Vogelbaum","year":"2022","unstructured":"Vogelbaum M, Brown P, Messersmith H, Brastianos P, Burri S, Cahill D, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. JCO. 2022;40:492\u2013516.","journal-title":"JCO"},{"issue":"6","key":"15224_CR5","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","volume":"23","author":"M Kuksis","year":"2021","unstructured":"Kuksis M, Gao Y, Tran W, Hoey C, Kiss A, Komorowski AS, et al. The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro-oncol. 2021;23(6):894\u2013904.","journal-title":"Neuro-oncol"},{"issue":"4","key":"15224_CR6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/PPO.0000000000000126","volume":"21","author":"IJ Fidler","year":"2015","unstructured":"Fidler IJ. The biology of brain metastasis: challenges for therapy. Cancer J. 2015;21(4):284\u201393.","journal-title":"Cancer J"},{"issue":"8","key":"15224_CR7","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamaoncol.2017.0001","volume":"3","author":"AM Martin","year":"2017","unstructured":"Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, et al. Brain metastases in newly diagnosed breast cancer: a population-based study. JAMA Oncol. 2017;3(8):1069\u201377.","journal-title":"JAMA Oncol"},{"issue":"4","key":"15224_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.adro.2019.07.006","volume":"4","author":"JA Bovi","year":"2019","unstructured":"Bovi JA, Pugh SL, Sabsevitz D, Robinson CG, Paulson E, Mehta MP, et al. Pretreatment volume of MRI-determined white matter injury predicts neurocognitive decline after hippocampal avoidant whole-brain radiation therapy for brain metastases: secondary analysis of NRG oncology radiation therapy oncology group 0933. Adv Radiat Oncol. 2019;4(4):579\u201386.","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"15224_CR9","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1016\/j.clbc.2018.11.001","volume":"19","author":"W Mainwaring","year":"2019","unstructured":"Mainwaring W, Bowers J, Pham N, Pezzi T, Shukla M, Bonnen M, et al. Stereotactic radiosurgery versus whole brain radiation therapy: a propensity score analysis and predictors of care for patients with brain metastases from breast cancer. Clin Breast Cancer. 2019;19(2):e343\u201351.","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"15224_CR10","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1080\/0284186X.2023.2260942","volume":"62","author":"JF Depner","year":"2023","unstructured":"Depner JF, Berg T, Ejlertsen B, Andreasen LW, M\u00f8ller S, Maraldo MV. Treating brain metastases in metastatic breast cancer: outcomes after stereotactic radiosurgery examined in a retrospective, single-center cohort analysis. Acta Oncol. 2023;62(11):1502\u201310.","journal-title":"Acta Oncol"},{"issue":"24","key":"15224_CR11","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1200\/JCO.20.02822","volume":"39","author":"NU Lin","year":"2021","unstructured":"Lin NU, Pegram M, Sahebjam S, Ibrahim N, Fung A, Cheng A, et al. Pertuzumab plus high-dose trastuzumab in patients with progressive brain metastases and HER2-positive metastatic breast cancer: primary analysis of a phase II study. J Clin Oncol. 2021;39(24):2667\u201375.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15224_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15623","volume":"8","author":"C-F Cho","year":"2017","unstructured":"Cho C-F, Wolfe JM, Fadzen CM, Calligaris D, Hornburg K, Chiocca EA, et al. Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents. Nat Commun. 2017;8(1):15623.","journal-title":"Nat Commun"},{"issue":"7","key":"15224_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597\u2013609.","journal-title":"N Engl J Med"},{"issue":"22","key":"15224_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225612","volume":"14","author":"IM Werter","year":"2022","unstructured":"Werter IM, Remmelzwaal S, Burchell GL, de Gruijl TD, Konings IR, van der Vliet HJ, et al. Systemic therapy for patients with HER2-positive breast cancer and brain metastases: a systematic review and meta-analysis. Cancers (Basel). 2022;14(22):5612.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"15224_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","volume":"9","author":"NU Lin","year":"2023","unstructured":"Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, et al. Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol. 2023;9(2):197\u2013205.","journal-title":"JAMA Oncol"},{"issue":"12","key":"15224_CR16","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","volume":"30","author":"N Harbeck","year":"2024","unstructured":"Harbeck N, Ciruelos E, Jerusalem G, M\u00fcller V, Niikura N, Viale G, et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat Med. 2024;30(12):3717\u201327.","journal-title":"Nat Med"},{"issue":"7","key":"15224_CR17","first-page":"953","volume":"5","author":"MF Press","year":"1990","unstructured":"Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 1990;5(7):953\u201362.","journal-title":"Oncogene"},{"issue":"4","key":"15224_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","volume":"14","author":"JS Ross","year":"2009","unstructured":"Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti\u2013HER-2 therapy and personalized medicine. Oncologist. 2009;14(4):320\u201368.","journal-title":"Oncologist"},{"issue":"7","key":"15224_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrm1962","volume":"7","author":"A Citri","year":"2006","unstructured":"Citri A, Yarden Y. EGF\u2013ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7(7):505\u201316.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"15224_CR20","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1158\/1535-7163.MCT-19-0873","volume":"19","author":"A Kulukian","year":"2020","unstructured":"Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, et al. Preclinical activity of HER2-selective tyrosine kinase inhibitor Tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol Cancer Ther. 2020;19(4):976\u201387.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"15224_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1012509","volume":"2022","author":"S Zhang","year":"2022","unstructured":"Zhang S, Fan S, Wang Z, Hou W, Liu T, Yoshida S, et al. Capecitabine regulates HSP90AB1 expression and induces apoptosis via Akt\/SMARCC1\/AP-1\/ROS axis in T cells. Oxid Med Cell Longev. 2022;2022(1):1012509.","journal-title":"Oxid Med Cell Longev"},{"key":"15224_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4143-x","volume":"18","author":"H Maadi","year":"2018","unstructured":"Maadi H, Nami B, Tong J, Li G, Wang Z. The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2. BMC Cancer. 2018;18:1\u201314.","journal-title":"BMC Cancer"},{"issue":"7","key":"15224_CR23","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S1470-2045(18)30256-0","volume":"19","author":"R Murthy","year":"2018","unstructured":"Murthy R, Borges VF, Conlin A, Chaves J, Chamberlain M, Gray T, et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(7):880\u20138.","journal-title":"Lancet Oncol"},{"issue":"23","key":"15224_CR24","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.20.00775","volume":"38","author":"NU Lin","year":"2020","unstructured":"Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, et al. Intracranial efficacy and survival with Tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38(23):2610\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"15224_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","volume":"33","author":"G Curigliano","year":"2022","unstructured":"Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2\u2009+\u2009metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022;33(3):321\u20139.","journal-title":"Ann Oncol"},{"issue":"4","key":"15224_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16040445","volume":"16","author":"O Bragina","year":"2024","unstructured":"Bragina O, Tashireva L, Loos D, Chernov V, Hober S, Tolmachev V. Evaluation of approaches for the assessment of HER2 expression in breast cancer by radionuclide imaging using the scaffold protein [99mTc] Tc-ADAPT6. Pharmaceutics. 2024;16(4):445.","journal-title":"Pharmaceutics"},{"issue":"1","key":"15224_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03458-3","volume":"24","author":"L Amrell","year":"2024","unstructured":"Amrell L, B\u00e4r E, Glasow A, Kortmann R-D, Seidel C, Patties I. Enhanced anti-tumor effects by combination of Tucatinib and radiation in HER2-overexpressing human cancer cell lines. Cancer Cell Int. 2024;24(1):277.","journal-title":"Cancer Cell Int"},{"issue":"5","key":"15224_CR28","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/neuonc\/noz006","volume":"21","author":"JM Kim","year":"2019","unstructured":"Kim JM, Miller JA, Kotecha R, Chao ST, Ahluwalia MS, Peereboom DM, et al. Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis. Neuro-oncol. 2019;21(5):659\u201368.","journal-title":"Neuro-oncol"},{"issue":"1","key":"15224_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11060-023-04402-7","volume":"164","author":"VM Khatri","year":"2023","unstructured":"Khatri VM, Mills MN, Oliver DE, Yu H-HM, Vogelbaum MA, Forsyth PA, et al. Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases. J Neurooncol. 2023;164(1):191\u20137.","journal-title":"J Neurooncol"},{"issue":"5","key":"15224_CR30","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.ijrobp.2023.07.019","volume":"118","author":"IA Kim","year":"2024","unstructured":"Kim IA, Winter KA, Sperduto PW, De Los Santos JF, Peereboom DM, Ogunleye T, et al. Concurrent lapatinib with brain radiation therapy in patients with HER2\u2009+\u2009Breast cancer with brain metastases: NRG oncology\u2013KROG\/RTOG 1119 phase 2 randomized trial. Int J Radiation Oncology* Biology* Phys. 2024;118(5):1391\u2013401.","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"key":"15224_CR31","doi-asserted-by":"crossref","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Inter n Med. 2013;158(3):200-07.","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"issue":"1","key":"15224_CR32","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas dermo-sifiliograficas. 2021;112(1):90\u20132.","journal-title":"Actas dermo-sifiliograficas"},{"issue":"2","key":"15224_CR33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"3","key":"15224_CR34","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"15224_CR35","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/0163278705275341","volume":"28","author":"PS Brucker","year":"2005","unstructured":"Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and cancer patient norms for the functional assessment of cancer therapy-general (FACT-G). Eval Health Prof. 2005;28(2):192\u2013211.","journal-title":"Eval Health Prof"},{"issue":"5","key":"15224_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, Charro Fd. EQ-SD: a measure of health status from the EuroQol group. Ann Med. 2001;33(5):337\u201343.","journal-title":"Ann Med"},{"key":"15224_CR37","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2165\/00019053-199813060-00005","volume":"13","author":"X Badia","year":"1998","unstructured":"Badia X, Herdman M, Kind P. The influence of ill-health experience on the valuation of health. Pharmacoeconomics. 1998;13:687\u201396.","journal-title":"Pharmacoeconomics"},{"key":"15224_CR38","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s11136-012-0322-4","volume":"22","author":"M Janssen","year":"2013","unstructured":"Janssen M, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22:1717\u201327.","journal-title":"Qual Life Res"},{"issue":"2","key":"15224_CR39","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","volume":"47","author":"E Shaw","year":"2000","unstructured":"Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000;47(2):291\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"15224_CR40","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jamaoncol.2023.4492","volume":"9","author":"ES Lebow","year":"2023","unstructured":"Lebow ES, Pike LR, Seidman AD, Moss N, Beal K, Yu Y. Symptomatic necrosis with antibody-drug conjugates and concurrent stereotactic radiotherapy for brain metastases. JAMA Oncol. 2023;9(12):1729\u201333.","journal-title":"JAMA Oncol"},{"issue":"5","key":"15224_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100561","volume":"7","author":"R Wuerstlein","year":"2022","unstructured":"Wuerstlein R, Ellis P, Montemurro F, Torres AA, Delaloge S, Zhang Q, et al. Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer. ESMO Open. 2022;7(5):100561.","journal-title":"ESMO Open"},{"issue":"17","key":"15224_CR42","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1200\/JCO.2004.01.175","volume":"22","author":"NU Lin","year":"2004","unstructured":"Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22(17):3608\u201317.","journal-title":"J Clin Oncol"},{"key":"15224_CR43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-012-2243-x","volume":"136","author":"ND Arvold","year":"2012","unstructured":"Arvold ND, Oh KS, Niemierko A, Taghian AG, Lin NU, Abi-Raad RF, et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat. 2012;136:153\u201360.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"15224_CR44","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/annonc\/mdl064","volume":"17","author":"BC Pestalozzi","year":"2006","unstructured":"Pestalozzi BC, Zahrieh D, Price K, Holmberg S, Lindtner J, Collins J, et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the international breast cancer study group (IBCSG). Ann Oncol. 2006;17(6):935\u201344.","journal-title":"Ann Oncol"},{"issue":"6063","key":"15224_CR45","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1126\/science.1206936","volume":"334","author":"JI Alvarez","year":"2011","unstructured":"Alvarez JI, Dodelet-Devillers A, Kebir H, Ifergan I, Fabre PJ, Terouz S, et al. The hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science. 2011;334(6063):1727\u201331.","journal-title":"Science"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15224-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15224-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15224-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T19:02:14Z","timestamp":1768158134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15224-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15224"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15224-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol (2020-AHL-001) was approved by the Miami Cancer Institute institutional review board (IRB study number 1336222) in August 2023. Before study participation, written and informed consent for participation is obtained from all patients after risks and benefits have been explained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"All authors provide consent for publication of this manuscript. The investigators will provide a model consent form and other study documents upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"Zouina Sarfraz\n                      \u00a0\u2013 No COI\n                      Ahmad Ozair\n                      \u00a0\u2013 No COI\n                      Mainak Bardhan\n                      \u00a0\u2013 No COI\n                      Amy K. Starosciak\n                      Consulting: Viz.ai (2022)\n                      Dilanis C. Perche\n                      Consulting: AstraZeneca, Novocure, Zai LabHonoraria: AstraZeneca, Novocure, Zai LabTravel Support: Novocure\n                      Lydia C. Hodgson\n                      \u00a0\u2013 No COI\n                      Yazmin Odia\n                      Clinical Trial Support: Blue Earth Diagnostics, Cantex Pharmaceuticals, Chimerix, CNSPharmaceuticals, Exelixis, MimiVax, Merck, Novocure, VBI VaccinesConsulting: PharPoint ResearchAdvisory Board: Modifi BioDSMB: GammaTile\n                      Minesh P. Mehta\n                      Consulting\/Honoraria: AIQ, Telix, Kazia, Novocure, Chimerix, MevionStock: Chimerix\n                      Rupesh R. Kotecha\n                      Grants\/Contracts (Institution): Medtronic, Blue Earth Diagnostics, NovoCure, GT MedicalTechnologies, AstraZeneca, Exelixis, Viewray, Brainlab, Cantex Pharmaceuticals, Ion BeamApplications, Kazia TherapeuticsConsulting (Personal): Kazia Therapeutics, Elekta AB, Viewray, Castle Biosciences, NovoCure,Telix PharmaceuticalsHonoraria (Personal): Elekta AB, Accuray, NovoCure, Viewray, Elsevier, Brainlab, PeerviewInstitute, Ion Beam ApplicationsTravel Support (Personal): Elekta AB, NovoCure, Peerview Institute, Brainlab, Viewray, GTMedical TechnologiesAdvisory\/DSMB (Personal): Viewray (Advisory Board), GT Medical (DSMB), Insightec, Plus\u00a0Therapeutics\n                      Michael W. McDermott\n                      Consulting: ZAP, Diende, Light Helmet\n                      Arun Maharaj\n                      \u00a0\u2013 No COI\n                      Ana Cristina Sandoval Leon\n                      Advisory Board: AstraZeneca, Stemline, GileadGrant Funding: Gilead\n                      Reshma Mahtani\n                      Consultant\/Advisor: Agendia, Arvinas, AstraZeneca, Bicycle Therapeutics, Daiichi, Genentech,Gilead, Hologic, Lilly, Novartis, Pfizer, Puma, StemlineResearch Support (Institution): Gilead\n                      Manmeet S. Ahluwalia\n                      Grants: Pfizer.Consulting: Bayer, Xoft, Nuvation Bio, Apollomics, Viewray, Varian Medical Systems, AnHeartTherapeutics, Theraguix, Menarini Ricerche, Sumitomo Pharma Oncology, Autem Therapeutics,GT Medical Technologies, Modifi Biosciences, Bugworks, Allovir, EquilliumBio, VBIVaccines, Servier Pharmaceuticals, Incyte, Recordati.Stock\/Stock Options: Mimivax, MedInnovate Advisors LLC, Modifi Biosciences, Trisalus\u00a0Lifesciences, LiveAI.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}